Retatrutide and Microdosing: What the Triple Agonist Trials Show at the Low End of the Dose Curve

On May 21, 2026, Eli Lilly reported that people on the highest dose of retatrutide had lost a quarter of their body weight over 80 weeks. A subgroup pushed to the maximum tolerated dose reached 30 percent at two years. No incretin medicine has produced numbers like that in a phase 3 trial.

Retatrutide is the third step in a sequence. Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, adding GIP. Retatrutide acts on three, adding the glucagon receptor, which is the part that changes the biology rather than just the dose. Glucagon raises energy expenditure and tells the liver to burn fat, so the drug does something to the output side of the energy equation that the earlier medicines do not. The result in TRIUMPH-1 was 25.0 percent weight loss at 12 mg against 3.9 percent on placebo, and in a 2024 substudy, liver fat fell by more than 80 percent at the higher doses.

This site is interested in the other end of the curve. The retatrutide programme includes a 1 mg arm, which is the lowest weekly dose of any modern incretin drug to be carried through a year long trial, and it includes a direct test of whether a smaller starting dose reduces side effects. Those two things, along with the glucagon side effects that come with the third receptor, are what this article covers. Retatrutide is not approved anywhere as of this writing. Nothing below is a protocol.

What is retatrutide and why does it act on three receptors?

The glucagon receptor is the part that changes the biology

Retatrutide is a single peptide, engineered from the glucagon backbone, that binds and activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. It carries a fatty acid chain that binds albumin in the blood, which gives it a half life of about six days and supports once weekly injection. Lilly's development code was LY3437943. The company's phase 2 trials in obesity and type 2 diabetes were published in 2023, and the phase 3 TRIUMPH programme began reporting in December 2025.

GLP-1 and GIP receptor activation work mostly on the intake side of the energy balance. They slow gastric emptying, act on appetite circuits in the hindbrain and hypothalamus, and improve insulin secretion. Glucagon receptor activation works on the output side. Glucagon is the hormone the pancreas releases during fasting to keep blood glucose up, and its receptor is dense in the liver, where activation increases fat oxidation, reduces fat synthesis, and raises hepatic energy expenditure. In animal models and early human studies, adding glucagon activity increased total energy expenditure by several percent, which over months compounds into additional weight loss and, more strikingly, a direct draining of liver fat.

The reason glucagon was not used on its own is obvious from its job: it raises blood glucose. Pairing it with GLP-1 and GIP, both of which lower glucose, is what makes the combination workable. The balance matters. Retatrutide was designed with relatively weaker glucagon activity than its GLP-1 activity, so that the glucose raising effect is more than covered. The phase 2 diabetes trial confirmed the balance holds: A1c fell by about 2 percentage points at 12 mg over 36 weeks, comparable to tirzepatide, with weight loss of about 17 percent.

How much weight did people lose in the phase 3 TRIUMPH trials?

Three readouts so far, with the cardiovascular trials still to come

Participants in TRIUMPH-1 lost about 17.6 percent of body weight at 4 mg, 23.7 percent at 9 mg, and 25.0 percent at 12 mg over 80 weeks, against 3.9 percent on placebo. The trial enrolled 2,339 adults with obesity, or overweight with at least one weight related condition, and no diabetes. It also included a second stage: 532 participants with a BMI of 35 or higher were escalated to their maximum tolerated dose for a further 24 weeks, and that group reached about 30 percent weight loss at 104 weeks. The trial was reported by Lilly in May 2026 and is the anchor result for the programme.

TRIUMPH-4 reported first, in December 2025. It enrolled adults with obesity and painful knee osteoarthritis, and the 12 mg arm lost about 28.7 percent over 68 weeks, with substantial improvement in knee pain scores. That figure is higher than TRIUMPH-1 partly because the population was heavier at baseline and partly because of trial design differences, and it should not be read as a different drug effect. TRANSCEND-T2D-1, reported in March 2026, tested retatrutide in adults with type 2 diabetes and found about 16.8 percent weight loss at 12 mg over 40 weeks, with A1c reductions of around 2 percentage points. People with diabetes lose less weight on every incretin drug, and retatrutide follows the pattern.

TRIUMPH-2 in type 2 diabetes with obesity and TRIUMPH-3 in people with established cardiovascular disease are expected to report later in 2026. TRIUMPH-Outcomes, the cardiovascular and kidney outcomes trial, is running on a longer timeline. Lilly has said it intends to file with the FDA in the first quarter of 2027, which puts the earliest plausible approval late in 2027. A pre-approval expanded access programme opened in 2026 for a narrow set of patients.

What does the low end of the retatrutide dose curve show?

A 1 mg arm, a 4 mg arm, and a test of starting dose

The 1 mg dose produced about 8.7 percent weight loss over 48 weeks against 2.1 percent on placebo, and the 4 mg dose produced about 17.1 percent. Put against the 24.2 percent at 12 mg, that is 36 percent of the top dose effect from 8 percent of the dose, and 71 percent of the effect from a third of the dose. The same shape appears in TRIUMPH-1, where 4 mg delivered 17.6 of the 25.0 percent at 12 mg, or 70 percent. Every incretin drug studied at more than two doses has produced a curve like this, and retatrutide is no exception. The first milligram does far more work per milligram than the last.

The 1 mg arm is worth attention for another reason. Its gastrointestinal side effect rates were close to placebo: nausea in roughly one in eight participants in both arms, vomiting in about 3 percent. Discontinuation for adverse events was about 6 percent, which is higher than the placebo arm's zero, but the same as the 4 mg arm and well below the 11 to 16 percent at 8 mg and 12 mg. Eight point seven percent of body weight, with a side effect profile that placebo would not distinguish on nausea alone, is a meaningful data point for anyone who thinks about exposure rather than maximum effect. It was a single arm of about 50 people, and it was not carried into phase 3, so it will remain a phase 2 result unless a maintenance or low dose trial picks it up.

The phase 2 design also included a direct test of starting dose. The 8 mg and 12 mg targets were each reached by two escalation paths, one starting at 2 mg and one starting at 4 mg. Arms that started at 2 mg had fewer gastrointestinal events than arms that started at 4 mg, even though they ended at the same dose. This is the principle behind slow escalation and gentle ramp protocols, and it is unusual to see it tested within a single randomised trial rather than inferred across trials. Lilly used the slower start in phase 3.

What did retatrutide do to liver fat?

The clearest signature of the glucagon receptor

Liver fat fell by about 43 percent at 1 mg, 57 percent at 4 mg, 81 percent at 8 mg, and 82 percent at 12 mg over 48 weeks, against essentially no change on placebo, in a substudy of the phase 2 obesity trial published in Nature Medicine in 2024. The substudy included 98 participants who had at least 10 percent liver fat on MRI at baseline, the threshold for metabolic dysfunction associated steatotic liver disease, or MASLD. On the two higher doses, more than 85 percent of participants ended the study with liver fat below 5 percent, which is the normal range.

The size of the effect is the point. Semaglutide and tirzepatide also reduce liver fat, but they do so roughly in proportion to weight loss, because the liver empties its fat stores as the whole body does. Retatrutide's liver fat reduction ran ahead of its weight loss at every dose, and the gap was widest at the low end: 1 mg produced about a third of the top dose weight loss but about half of the top dose liver fat reduction. That pattern is what a direct hepatic effect looks like. The glucagon receptor is expressed on liver cells and its activation switches the liver toward fat oxidation, independent of what the rest of the body is doing.

Fatty liver is covered in more detail elsewhere on this site, but the retatrutide data reframe one part of that discussion. The argument for a low dose has always been that the front loaded shape of the dose curve delivers a large share of the metabolic benefit at a small share of the exposure. For liver fat, the retatrutide curve is even more front loaded than it is for weight, which makes the liver the organ where a lower dose of a glucagon containing drug would be expected to show the most. That is an inference from a 98 person substudy, not a trial result, and Lilly has a dedicated MASH trial underway to test it properly.

What side effects come from the glucagon receptor?

Heart rate, skin sensation, and the open cardiovascular question

Resting heart rate rose by up to about 7 beats per minute at the higher retatrutide doses in phase 2, peaked around week 24, and partly reversed by week 48 while participants stayed on the drug. Semaglutide and tirzepatide raise heart rate by around 2 to 4 beats per minute at their approved doses, so retatrutide roughly doubles the effect. Glucagon acts directly on the heart, increasing rate and contractility, which is why glucagon injection is used in emergency medicine for certain drug overdoses. The peak and partial reversal suggest the body adapts, but the mechanism of adaptation is not established, and a sustained rise of several beats per minute is not trivial for someone with a rhythm disorder or established heart disease.

A small share of phase 2 participants reported abnormal skin sensations, described as tingling, heightened sensitivity, or pins and needles, that appeared at the higher doses and mostly resolved with time or dose reduction. This is called dysesthesia, and it has been reported with other glucagon receptor agonists including survodutide. The cause is not known. It was uncommon, in the range of 5 to 10 percent at the top doses, and did not lead to many discontinuations, but it is a side effect that a semaglutide or tirzepatide user would not recognise.

The class warnings carry over. Pancreatitis, gallbladder disease, and the thyroid C cell tumour caution apply to retatrutide as they do to every incretin peptide. TRIUMPH-3, in people with established cardiovascular disease, and TRIUMPH-Outcomes, the dedicated outcomes trial, are the studies that will settle whether the heart rate rise translates into events. Until they report, the heart rate signal is the main reason a triple agonist is not simply a bigger tirzepatide.

What is worth knowing and raising with a prescriber?

Five points, none of which are a protocol

Everything below is context for a conversation rather than an instruction. Retatrutide cannot be prescribed outside a trial or the expanded access programme, and nothing here sets a dose or chooses a product.

What is genuinely unresolved here?

Three gaps worth naming

Nobody has followed a low retatrutide dose beyond 48 weeks. The 1 mg arm was about 50 people in a phase 2 trial, and it was dropped from phase 3, where the floor is 4 mg. Whether 1 mg holds weight over two years, whether its side effect profile stays close to placebo, and what it does to heart rate over that period are not known. The phase 3 4 mg data are solid and run 80 weeks, but 4 mg is not a low dose in any meaningful sense; it delivered more weight loss than semaglutide 2.4 mg.

The cardiovascular question is open. A drug that raises resting heart rate by several beats per minute for months, in a population with a high baseline cardiovascular risk, needs an outcomes trial before the trade can be judged. Semaglutide and tirzepatide have now both shown cardiovascular benefit in dedicated trials, and the expectation is that the much larger weight loss from retatrutide will outweigh the heart rate effect. Expectation is not evidence, and TRIUMPH-Outcomes has not reported.

Muscle and bone at 25 to 30 percent weight loss have not been characterised. Every incretin trial finds that a share of lost weight is lean tissue, typically a quarter to a third, and the concern grows with the total. At the weight loss retatrutide produces, the absolute lean mass lost is larger than anything seen with earlier drugs, and the body composition substudies from TRIUMPH have not been published. The resistance training and protein arguments made elsewhere on this site apply with more force here, not less.

Frequently Asked Questions